This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Apr 2014

FDA Approves New Hand-Held Auto-Injector to Reverse Opioid Overdose?

Yesterday (3 April) FDA approved a prescription treatment that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose. Evzio (naloxone hydrochloride injection) rapidly delivers a single dose of the drug naloxone via a hand-held auto-injector that can be carried in a pocket or stored in a medicine cabinet.

 

It is intended for the emergency treatment of known or suspected opioid overdose, characterised by decreased breathing or heart rates, or loss of consciousness.

 

Drug overdose deaths, driven largely by prescription drug overdose deaths, are now the leading cause of injury death in the US — surpassing motor vehicle crashes. In 2013, the Centers for Disease Control and Prevention reported the number of drug overdose deaths had steadily increased for more than a decade.

 

Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for overdose. However, existing naloxone drugs require administration via syringe and are most commonly used by trained medical personnel in emergency departments and ambulances.

 

“Overdose and death resulting from misuse and abuse of both prescription and illicit opioids has become a major public health concern in the US,” said Bob Rappaport, MD, director of the Division of Anesthesia, Analgesia, and Addiction Products in the FDA’s Center for Drug Evaluation and Research. “Evzio is the first combination drug-device product designed to deliver a dose of naloxone for administration outside of a health care setting. Making this product available could save lives by facilitating earlier use of the drug in emergency situations.”

 

Evzio is being approved ahead of the product’s prescription drug user fee goal date of 20 June 2014, the date the agency was originally scheduled to complete review of the drug application.

 

Evzio’s approval is also the result of efforts by several federal agencies. Naloxone has been a part of the White House’s Office of National Drug Control Policy’s National Drug Control Strategy since 2012. The FDA co-chairs an HHS inter-departmental working group on naloxone, which helped co-ordinate an 12 April 2012, meeting regarding access to naloxone products.

 

Evzio is manufactured for kaléo, Inc., of Richmond, Va.

Related News